Baricitinib was generally well-tolerated. Acne was the most common adverse event (17.6%), followed by dyslipidemia (7.8%). Asthenia, elevated liver enzymes, and weight gain each occurred in fewer than ...
Refractory dry eye in patients with systemic comorbidities can be challenging to manage because the underlying condition or its treatments may contribute to ocular surface disease. In this Q&A ...
Côte St. Luc City speaks out on Chanukah massacre in Australia ...
Here are our top highlights from AAD 2025 that include safety of topical JAK inhibitors, climate impacts on skin health, ...
Nemolizumab, which targets the interleukin-31 pathway, rapidly improves itch and sleep in people with atopic dermatitis and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback